Ovarian Remnant Syndrome: A Case Report

Introduction

Ovarian Remnant Syndrome (ORS) is a rare complication that arises as a consequence of residual ovarian tissue after an oophorectomy. It is characterized by pelvic pain, which can be chronic or cyclic. Surgery is considered the primary treatment but can present with certain difficulties [1]. We report an unusual case of ORS successfully treated with Gonadotropin-releasing hormone agonist (GnRHa). Because the treatment was multidisciplinary, she started taking gabapentin when she was already using a GnRHa. One month later, she reported clinical improvement. She stopped taking the GnRHa after 6 months and underwent magnetic resonance imaging that showed a suspected adnexal malignancy. She underwent laparotomy, and the remnant ovary was removed (Figure 1). Histopathological analysis revealed corpus albicans.

Case Report

A 44-year-old Caucasian woman who underwent hysterectomy and bilateral adnexectomy 3 years earlier presented with pelvic pain. Her primary care gynecologist prescribed continuous oral contraceptives, but the patient continued to have pelvic pain. One month after her initial presentation, the patient was prescribed and started taking a GnRHa. She also started taking 10 mg gabapentin daily, which improved her symptoms. One month later, she reported clinical improvement. She stopped taking the GnRHa after 6 months and underwent magnetic resonance imaging that showed a suspected adnexal malignancy. She underwent laparotomy, and the remnant ovary was removed (Figure 1). Histopathological analysis revealed corpus albicans.

Discussion

Ovarian remnant syndrome results from an unintentionally incomplete oophorectomy. In most patients, it seems that ORS results from an incidental implantation of ovarian tissue rather than an incomplete excision of a lesion [2]. Symptoms most often occur within the first 5 years of a previous surgery, although reports have shown patients whose initial surgeries were more than 20 years ago [1]. Dense periovian adhesions and ovarian enlargement can make the identification of ovarian tissue difficult, and they are considered the predisposing factors of this disease. Both of those factors are present in severe endometriosis, the most typical preexisting disease [1]. The risk factors include pelvic inflammatory disease and adhesion [2].

The recurrence of pelvic symptoms is associated with the development of a hormonally functional follicular or corpus luteum cyst within the ovarian fragment, or with reactivation of endometriosis [3]. When the remaining ovary continues to produce sex steroids, the FSH levels remain low. Although the absence of this finding does not rule out the diagnosis, FSH levels <40 IU/dL indicate the presence of an ovarian remnant. A definitive diagnosis involves histologic confirmation of ovarian tissue obtained from the subsequent surgery [1].

The main treatment is surgery. Moreover, excision of remnant tissue requires retroperitoneal dissection [1]. Ovarian fragments may be difficult to localize, and reappearance of new fragments is
possible. Ovulation-inducing drugs administered before surgery have been successful in stimulating the enlargement of such fragments, facilitating their location and removal [3].

Most clinical treatments do not seem to relieve symptoms and are often directed toward ovarian suppression. These include oral contraceptives such as danazol, GnRHa, and progestins [1].

Clinical treatments may increase the risk of ovarian cancer. There are controversies about the value of prophylactic oophorectomy in women with no increased risk for ovarian cancer. Epidemiological evidence suggest that annually about 1,000 cases of ovarian cancer are prevented for every 300,000 oophorectomies performed at the time of an elective hysterectomy in women over 40 years [4]. However, the risk of a woman with BRCA-1/BRCA-2 mutations developing ovarian cancer over a lifetime ranges from 16% to 54% [5]. If some ovary tissue is left in this population, there is a significant risk of ovarian cancer and clinical treatment is not indicated.

Gabapentin, a synthesized form of gamma-aminobutyric acid, an inhibitory neurotransmitter, is being increasingly prescribed for chronic pelvic pain and requires titration to achieve an efficacious dose [6]. Chronic gabapentin exposure reduces calcium currents because it binds to the α2δ-1 subunit of calcium channels. As voltage-gated calcium channels regulate various actions in the body, subtypes modulating pain are reduced [7]. In this case, it was used in association with a GnRHa with appreciable pain relief.

A medline search with the terms “remnant ovarian syndrome and gabapentin” revealed no previous reports about the use of gabapentin for ovarian remnant syndrome.

Conclusion

Although the literature reports failure in the clinical treatment of ORS, pain relief was obtained in this case by administering a GnRHa in association with gabapentin. Avoiding surgery with its greater risks is desirable in ORS. However, the question remains whether ORS can be treated without surgery. We do not know if the pain improvement in this case was due to the association between GnRHa and gabapentin, or gabapentin alone. More studies should be performed to assess the long-term effects of gabapentin.

References